Company: PRME
Filing Date: 2025-07-14
Form Type: DEF 14A
Source: 0001193125-25-158716
Chunk: 17

Company: Prime Medicine, Inc.
Filing Date: 2025-07-14
Form: DEF 14A
Chunk 17
---
 the Option Repricing If approved by the stockholders at the Special Meeting, effective as of the Repricing Date, the per share exercise price of each Eligible Option held by an Eligible Optionholder who is an employee of the Company or a member of the Board, as applicable, through the Repricing Date will automatically be reduced to the Repriced Exercise Price; provided, however, that an Eligible Option will revert to its Original Price if (i) such Eligible Option is exercised prior to the applicable Retention Date, (ii) an Eligible Optionholder’s Service Relationship is terminated by the Company for Cause prior to the applicable Retention Date, or (iii) an Eligible Optionholder resigns from the Company (including as a member of the Board) for any reason prior to the applicable Retention Date (provided that, for any Eligible Optionholder party to an employment agreement, offer letter or severance plan or policy pursuant to which such Eligible Optionholder is entitled to “good reason” protection, such Eligible Optionholder shall retain the Repriced Exercise Price if such Eligible Optionholder resigns for “good reason”). Notwithstanding the foregoing, in the event of (A) a Sale Event (as defined in the 2022 Plan or 2019 Plan, as applicable) prior to the applicable Retention Date, (B) the termination of the Eligible Optionholder’s Service Relationship by the Company without Cause or for “good reason” (as applicable) or (C) the Eligible Optionholder’s death or disability (as determined in accordance with the 2022 Plan or 2019 Plan, as applicable), each Eligible Option shall retain the Repriced Exercise Price to the extent it has not otherwise reverted to the Original Price in accordance with the foregoing and the ability to exercise such Eligible Option may be accelerated to earlier than the applicable Retention Date. Except for the reduction in the exercise price of the Eligible Options, the Option Repricing will have no other impact on the Eligible Options and all outstanding stock options under the Plans will continue to remain outstanding in accordance with the current terms and conditions set forth in the Plans and the applicable award agreements, including without limitation, any provisions with respect to vesting and term of the options. 11

The following table provides information as of June 30, 2025 regarding the Eligible Options, but excludes the number of shares underlying certain outstanding stock options granted under the Plans that will cease to be Eligible Options as of the